STOCK TITAN

Helius Medical Technologies, Inc. - HSDT STOCK NEWS

Welcome to our dedicated page for Helius Medical Technologies news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Medical Technologies stock.

Helius Medical Technologies, Inc. (symbol: HSDT) is a pioneering neurotechnology company headquartered in Newtown, Pennsylvania, dedicated to developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological diseases or trauma. The company’s flagship product, the Portable Neuromodulation Stimulator (PoNS®), is a novel medical device approved in Canada for the treatment of chronic balance deficits due to mild-to-moderate traumatic brain injury (mTBI) and gait deficits related to multiple sclerosis (MS). The PoNS® device works by delivering gentle electrical stimulation to the tongue's surface, which helps improve balance and gait through enhanced neuromodulation.

Recently, Helius Medical Technologies has achieved significant milestones, including expanding its clinical development program in collaboration with renowned institutions like the Shepherd Center and Brooks Rehabilitation. This expansion aims to further validate PoNS®'s efficacy for treating gait and balance deficits in chronic stroke survivors, highlighting the company’s commitment to broadening therapeutic applications.

In terms of partnerships, Helius has secured a meaningful collaboration with Lovell Government Services to introduce the PoNS® device to the U.S. Department of Veterans Affairs (VA) and other federal healthcare providers. This partnership aims to enhance the quality of life for veterans suffering from MS by providing access to innovative treatments. Real-world studies have shown that PoNS® Therapy can lead to clinically meaningful improvements in gait for all MS patients after 14 weeks of therapy.

Financially, Helius Medical Technologies is focusing on securing widespread reimbursement for the PoNS® device. The company recently received its first third-party reimbursement from a major insurance carrier, a crucial step towards establishing market pricing and expanding access. This follows the Centers for Medicare & Medicaid Services’ (CMS) establishment of unique Healthcare Common Procedure Coding System (HCPCS) codes for the PoNS® components.

Additionally, the PoNS® device is now available for purchase via the VA’s Federal Supply Schedule (FSS) and the GSA Advantage marketplace, ensuring quicker access for veterans and federal employees. The inclusion of PoNS® in these platforms underscores its potential as a game-changing therapy for those affected by neurological conditions, promoting neuroplasticity and improving patients' lives.

For more information about the PoNS® or Helius Medical Technologies, please visit www.heliusmedical.com.

Rhea-AI Summary
Helius Medical adds Montefiore Medical Center to its PoNS Therapeutic Experience Program for MS patients. Dr. Langston, a renowned researcher, joins the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. will release its second quarter 2023 financial results on August 10, 2023. The conference call will provide an update on the progress and plans surrounding the U.S. commercialization of PoNS®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
Helius Medical Technologies is expanding its trial in stroke patients from 12 to 60 participants. The trial will evaluate the effects of cranial-nerve non-invasive neuromodulation using PoNS Therapy on gait and dynamic balance in chronic stroke survivors. The company aims to leverage the breakthrough designation granted in August 2021 and pursue approval for stroke treatment in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.39%
Tags
conferences
-
Rhea-AI Summary

Helius Medical Technologies (NASDAQ: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced its participation in the LD Micro Invitational XIII 2023. The event will take place at the Luxe Sunset Boulevard Hotel in California.

President and CEO Dane Andreeff, along with CFO Jeff Mathiesen, will represent Helius at the conference. Their presentation is scheduled for Wednesday, June 7, 2023, at 4:00 PM PT. Interested parties can access the webcast through the provided link.

Investors and attendees wishing to arrange one-on-one meetings with Helius management are encouraged to contact LD Micro directly. This event provides an opportunity for Helius to showcase its innovative approach to neuromodulation therapy and engage with potential investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.28%
Tags

FAQ

What is the current stock price of Helius Medical Technologies (HSDT)?

The current stock price of Helius Medical Technologies (HSDT) is $0.4532 as of November 22, 2024.

What is the market cap of Helius Medical Technologies (HSDT)?

The market cap of Helius Medical Technologies (HSDT) is approximately 1.9M.

What does Helius Medical Technologies, Inc. do?

Helius Medical Technologies, Inc. develops, licenses, and acquires non-invasive technologies to treat symptoms caused by neurological diseases or trauma.

What is the Portable Neuromodulation Stimulator (PoNS®)?

The PoNS® is a medical device that delivers neurostimulation through the tongue to improve balance and gait, primarily for patients with mTBI and MS.

Where is Helius Medical Technologies headquartered?

The company is headquartered in Newtown, Pennsylvania.

What are the recent achievements of Helius Medical Technologies?

Recent achievements include expanding clinical development programs, partnering with Lovell Government Services, and securing third-party insurance reimbursement.

How does PoNS® Therapy work?

PoNS® Therapy involves delivering mild electrical impulses to the tongue, which stimulates cranial nerves to improve balance and gait through neuromodulation.

Is the PoNS® device approved for use in the United States?

In the U.S., the PoNS® is indicated as a short-term treatment for gait deficit due to MS symptoms, to be used with supervised therapeutic exercise.

What partnerships has Helius Medical Technologies formed?

Notable partnerships include collaborations with Lovell Government Services and institutions like the Shepherd Center and Brooks Rehabilitation.

How is the PoNS® device distributed to veterans?

The PoNS® device is available through the VA’s Federal Supply Schedule (FSS) and the GSA Advantage marketplace, facilitating access for veterans and federal employees.

What is the financial condition of Helius Medical Technologies?

Helius is focused on securing reimbursement for the PoNS® device and has achieved its first third-party insurance reimbursement, paving the way for broader financial stability.

Where can I find more information about Helius Medical Technologies?

For more information, visit the company's official website at www.heliusmedical.com.

Helius Medical Technologies, Inc.

Nasdaq:HSDT

HSDT Rankings

HSDT Stock Data

1.86M
3.71M
0.53%
5.87%
6.3%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
NEWTOWN